Missing out on effective care in idiopathic pulmonary fibrosis: Racial inequality in access to anti-fibrotic therapy

被引：0
|
作者：
Pascoe, Amy [1 ]
Smallwood, Natasha [1 ,2 ]
机构：
[1] Monash Univ, Cent Clin Sch, Resp Res, Alfred, Vic, Australia
[2] Alfred Hosp, Dept Resp & Sleep Med, Prahran, Vic, Australia
来源：
RESPIROLOGY | 2023年 / 28卷 / 11期
关键词：
antifibrotic agents; health disparities; health inequities; idiopathic pulmonary fibrosis; interstitial lung disease; mortality; social determinants of health; DISPARITIES; COPD;
D O I：
10.1111/resp.14594
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
See related article
引用
收藏
页码：978 / 979
页数：2
相关论文
共 50 条
  • [21] Clinical Characteristics of Progressive Pulmonary Fibrosis of Idiopathic Pulmonary Fibrosis Patients Who Receive Anti-fibrotic Agent
    Kishaba, T.
    Nagano, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [22] Notch in fibrosis and as a target of anti-fibrotic therapy
    Hu, Biao
    Phan, Sem H.
    PHARMACOLOGICAL RESEARCH, 2016, 108 : 57 - 64
  • [23] Evaluation of Extracellular Matrix Biomarkers in Response to Anti-Fibrotic Treatment of Idiopathic Pulmonary Fibrosis
    Jessen, H.
    Hoyer, N.
    Ronnow, S.
    Karsdal, M.
    Leeming, D. J.
    Sand, J. M.
    Shaker, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [24] A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
    Roach, Katy M.
    Sutcliffe, Amanda
    Matthews, Laura
    Elliott, Gill
    Newby, Chris
    Amrani, Yassine
    Bradding, Peter
    SCIENTIFIC REPORTS, 2018, 8
  • [25] A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
    Katy M. Roach
    Amanda Sutcliffe
    Laura Matthews
    Gill Elliott
    Chris Newby
    Yassine Amrani
    Peter Bradding
    Scientific Reports, 8
  • [26] Discrepancy between patient expectations and experiences with anti-fibrotic drugs in idiopathic pulmonary fibrosis
    Moor, Catharina
    Kimman, Merel L.
    van Manen, Mirjam J. G.
    Dirksen, Carmen D.
    Wijsenbeek, Marlies S.
    Van Jaarsveld, F. Xana
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [27] A review of Idiopathic Pulmonary Fibrosis patients on anti-fibrotic treatment in the mid west area
    Ryan, N.
    Ryan, P.
    Gleeson, E.
    Cullinan, M.
    Mcinerney, C.
    Casserly, B.
    O'Brien, A.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 (SUPPL 10) : S441 - S442
  • [28] Anti-Fibrotic Therapy Modulates Mortality Risk Associated with Circulating Plasma Biomarkers in Patients with Idiopathic Pulmonary Fibrosis
    Sarma, N.
    Adegunsoye, A. O.
    Alqalyoobi, S.
    Bowman, W. S.
    Lee, C.
    Pugashetti, J. V.
    Linderholm, A.
    Ma, S.
    Haczku, A.
    Strek, M. E.
    Noth, I.
    Oldham, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [29] ANTI-FIBROTIC THERAPY MODULATES MORTALITY RISK ASSOCIATED WITH CIRCULATING PLASMA BIOMARKERS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    Oldham, Justin
    Alqalyoobi, Shehabaldin
    Adegunsoye, Ayodeji
    Linderholm, Angela
    Hrusch, Cara
    Pugashetti, Janelle
    Boctor, Noelle
    Sperling, Anne
    Strek, Mary
    Noth, Imre
    CHEST, 2019, 156 (04) : 258A - 259A
  • [30] Anastomotic Outcomes in Idiopathic Pulmonary Fibrosis Patients Receiving Anti-Fibrotic Therapy: Experience of the Australian Lung Transplant Collaborative
    Mackintosh, J.
    Munsif, M.
    Thomson, C.
    Musk, M.
    Snell, G.
    Glanville, A.
    Chambers, D.
    Hopkins, P.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (04): : S89 - S90
12345